Improving treatment for colorectal cancer by targeting cell death mechanisms
Targeting defective necroptosis in colorectal cancer
['FUNDING_R01'] · UNIVERSITY OF SOUTHERN CALIFORNIA · NIH-10745648
This study is looking at a special way that cancer cells can die to help make colorectal cancer treatments work better, especially for patients whose cancer doesn't respond well to current therapies, with the hope of finding new options that could lead to improved results.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTHERN CALIFORNIA (nih funded) |
| Locations | 1 site (Los Angeles, UNITED STATES) |
| Trial ID | NIH-10745648 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of colorectal cancer treatments by investigating a specific type of cell death known as necroptosis. Researchers aim to understand how this process can be manipulated to overcome resistance to current therapies, particularly in patients whose cancer cells lack certain proteins that regulate necroptosis. By identifying new agents that can restore this cell death pathway, the study seeks to improve the response of colorectal cancer cells to existing chemotherapy drugs. Patients may benefit from new treatment options that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer, particularly those who have shown resistance to standard therapies.
Not a fit: Patients with colorectal cancer who have already responded well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic strategies that significantly improve treatment responses for colorectal cancer patients.
How similar studies have performed: While targeting necroptosis in cancer treatment is a relatively novel approach, preliminary studies have shown promise in similar contexts, indicating potential for success.
Where this research is happening
Los Angeles, UNITED STATES
- UNIVERSITY OF SOUTHERN CALIFORNIA — Los Angeles, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, LIN — UNIVERSITY OF SOUTHERN CALIFORNIA
- Study coordinator: ZHANG, LIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, Cancers